2024
Macrophage membrane-camouflaged biomimetic nanoparticles for rheumatoid arthritis treatment via modulating macrophage polarization
Zhou R, Xue S, Cheng Y, Chen Y, Wang Y, Xing J, Liu H, Xu Y, Lin Y, Pei Z, Wei X, Ding J, Li S, Wang K, Yao F, Zhao Y, Ding C, Hu W. Macrophage membrane-camouflaged biomimetic nanoparticles for rheumatoid arthritis treatment via modulating macrophage polarization. Journal Of Nanobiotechnology 2024, 22: 578. PMID: 39300463, PMCID: PMC11414146, DOI: 10.1186/s12951-024-02822-9.Peer-Reviewed Original ResearchConceptsCollagen-induced arthritisNanotherapeutic systemInflamed jointsRheumatoid arthritisMacrophage polarizationModulating macrophage polarizationDelay disease progressionDebilitating autoimmune diseaseChronic joint inflammationComprehensive in vitroAnti-inflammatory M2 phenotypeReduced synovial inflammationEnhanced cellular uptakeIntra-articular injectionRheumatoid arthritis treatmentPro-inflammatory M1Treatment optionsAutoimmune diseasesRepolarize macrophagesBiomimetic nanoparticlesDisease progressionMouse modelNanoparticlesTherapeutic strategiesSide effectsEfferocytosis: Unveiling its potential in autoimmune disease and treatment strategies
Xing J, Wang K, Xu Y, Pei Z, Yu Q, Liu X, Dong Y, Li S, Chen Y, Zhao Y, Yao F, Ding J, Hu W, Zhou R. Efferocytosis: Unveiling its potential in autoimmune disease and treatment strategies. Autoimmunity Reviews 2024, 23: 103578. PMID: 39004157, DOI: 10.1016/j.autrev.2024.103578.Peer-Reviewed Original ResearchClearance of apoptotic cellsApoptotic cellsDegradation of apoptotic cellsPhagocyte surface receptorsAutoimmune diseasesInternalize apoptotic cellsEfficient clearance of apoptotic cellsSelf-antigensRelease of self-antigensSystemic lupus erythematosusTreat autoimmune diseasesSignaling pathwayType 1 diabetesSurface receptorsImmunosuppressive signalsImmune toleranceLupus erythematosusImmune homeostasisTreatment strategiesEfferocytosis processEfficient clearanceInadequate clearanceTherapeutic strategiesImmune responsePhagocytes
2022
Blockade of ASIC1a inhibits acid-induced rat articular chondrocyte senescence through regulation of autophagy
Yang Y, Ding J, Chen Y, Ma G, Wei X, Zhou R, Hu W. Blockade of ASIC1a inhibits acid-induced rat articular chondrocyte senescence through regulation of autophagy. Human Cell 2022, 35: 665-677. PMID: 35075624, DOI: 10.1007/s13577-022-00676-7.Peer-Reviewed Original ResearchConceptsAcid-sensitive ion channel 1aChondrocyte senescenceRat articular chondrocytesSenescence-related markersExtracellular acidificationSenescence-associated secretory phenotypeTreatment of osteoarthritisPotential therapeutic strategySenescence-associated β-galactosidaseIon channel 1aProtein LC3B-IIArticular chondrocytesC28/I2 chondrocyte cell lineMatrix metalloproteinases genesChondrocyte cell lineTherapeutic strategiesChondrocyte damageControl groupROS expressionPsalmotoxin-1Secretory phenotypeChannel 1aChondrocyte autophagyLC3B-IIMetalloproteinases genes
2018
Necrostatin-1 ameliorates adjuvant arthritis rat articular chondrocyte injury via inhibiting ASIC1a-mediated necroptosis
Chen Y, Zhu C, Zhu F, Dai B, Song S, Wang Z, Feng Y, Ge J, Zhou R, Chen F. Necrostatin-1 ameliorates adjuvant arthritis rat articular chondrocyte injury via inhibiting ASIC1a-mediated necroptosis. Biochemical And Biophysical Research Communications 2018, 504: 843-850. PMID: 30219231, DOI: 10.1016/j.bbrc.2018.09.031.Peer-Reviewed Original ResearchConceptsRat articular cartilageRheumatoid arthritisNec-1Necrostatin-1Potential therapeutic strategyAcid-induced increaseChannel inhibitor amilorideArticular cartilage damageReceptor interacting protein 1Articular cartilageRIP1/RIP3Chondrocyte injuryAA ratsCartilage damageTherapeutic strategiesRA treatmentCartilage injuryPathophysiological processesPsalmotoxin-1Inhibitor necrostatin-1Expression of RIP1Inhibitor amilorideRIP1 inhibitor necrostatin-1Interacting protein 1ASIC1a
2016
Functions of interleukin‐34 and its emerging association with rheumatoid arthritis
Zhou R, Wu X, Xie Y, Dai B, Hu W, Ge J, Chen F. Functions of interleukin‐34 and its emerging association with rheumatoid arthritis. Immunology 2016, 149: 362-373. PMID: 27550090, PMCID: PMC5095491, DOI: 10.1111/imm.12660.Peer-Reviewed Original ResearchConceptsRheumatoid arthritisIL-34Inflammatory arthritisAutoimmune diseasesDevelopment of RAInterleukin-34Active rheumatoid arthritisSystemic autoimmune diseaseEffective treatment optionExtra-articular lesionsNovel therapeutic strategiesMononuclear phagocyte lineage cellsSynovial inflammationTreatment optionsSpecific monoclonal antibodiesTherapeutic strategiesTherapeutic targetArthritisMonoclonal antibodiesExperimental modelLineage cellsMultiple jointsReceptor ligandsInflammationDisease